A Study of Capecitabine In Combination With Docetaxel Vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer

This study has been terminated.
Sponsor:
Information provided by:
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT00087620
First received: July 12, 2004
Last updated: December 15, 2005
Last verified: December 2005

July 12, 2004
December 15, 2005
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00087620 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Study of Capecitabine In Combination With Docetaxel Vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Not Provided

To evaluate and compare the time to progression of the combination of capecitabine (825 mg/m2 twice daily) and docetaxel (75mg/m2 i.v.) to that of capecitabine (1000 mg/m2 twice daily) until progressive disease followed sequentially by docetaxel (75 mg/m2 i.v. D1 Q3W).

Not Provided
Interventional
Phase 4
Primary Purpose: Treatment
Breast Cancer
Drug: XELODA [capecitabine]
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • Have provided written informed consent prior to study specific screening procedures, with the understanding that the patient has the right to withdraw from the study at any time, without prejudice
  • Be female and at least 18 years of age. Note: must be 19 years of age if the patient is a resident of the state of Alabama
  • Be ambulatory (outpatient) and have a Karnofsky performance status of more than 70%
  • Have confirmed breast cancer with locally advanced and/or metastases
  • Have at least one site with defined tumor
  • Have met one of the study definitions of primary or nonprimary resistance to an anthracycline-containing therapy

Exclusion Criteria:

  • Pregnant/lactating women
  • Women of childbearing potential with either a positive or no pregnancy test
  • Women of childbearing potential unless using a reliable and appropriate contraceptive method (Postmenopausal women must have not had their period for at least 12 months to be considered of non-childbearing potential)
  • Prior treatment with chemotherapy in the advanced/metastatic setting
  • HER 2/neu positive status without prior treatment with trastuzumab
  • Prior treatment with IV bolus 5-FU, continuous 5-FU infusion, capecitabine or other oral fluoropyrimidines
  • Prior treatment with a taxane if less than 12 months passed from the time of therapy completion to relapse
  • Mitomycin C or nitrosoureas within 6 weeks preceding treatment start
  • Organ allografts requiring immunosuppressive therapy
  • Radiotherapy to the skeleton within 4 weeks of study treatment start or insufficient recovery from the effects of prior radiotherapy
  • Hormonal therapy within 10 days preceding study treatment start
  • Major surgery within 4 weeks prior to study treatment start, or lack of complete recovery from the effects of major surgery
  • Blood transfusions/growth factors to aid hematologic recovery within 2 weeks prior to study treatment start
  • Participation in any investigational drug study within 4 weeks preceding treatment start
  • Prior unanticipated severe reaction to fluoropyrimidine therapy
  • Known hypersensitivity to 5-fluorouracil, taxanes or any of the components of capecitabine
  • Requirement for concurrent use of the antiviral agent sorivudine or chemically related analogues
  • Evidence of CNS metastases
  • History of another malignancy within the last five years except cured basal cell carcinoma of skin and carcinoma
  • Clinically significant (i.e. active) cardiac disease
  • Abnormal laboratory values
  • Severe renal impairment
  • Serious uncontrolled intercurrent infections, or other serious uncontrolled concomitant disease
  • Lack of physical integrity of the upper GI tract
  • Life expectancy of less than 3 months
  • Unwilling/unable to comply with the protocol
Female
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00087620
ML17771
Not Provided
Not Provided
Hoffmann-La Roche
Not Provided
Not Provided
Hoffmann-La Roche
December 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP